Elores is a an anti-infective drug for treating life-threatening infections caused by gram-negative bacteria.
Cipla gained a percent intraday on October 18 after acquiring an anti-infective drug, Elores, from Venus Remedies.
The stock has rallied around 10 percent in the last fortnight. It was quoting at Rs 450.35, up Rs 4.05, or 0.91 percent, on the BSE at 1247 hours.
The Mumbai-based pharma company announced the acquisition of the novel and patented anti-infective product for the Indian market to further strengthen its presence in the branded critical care space and as a part of its agenda to contribute to the fight against anti-microbial resistance (AMR).
Elores is a novel combination of Ceftriaxone (a third generation beta-lactam cephalosporin), Sulbactam (a beta-lactamase inhibitor) and Disodium EDTA (an antibiotic resistance breaker) indicated for treating life-threatening infections caused by gram-negative bacteria.
The drug preserves the efficacy of the antibiotics, using appropriate antibiotic resistance breakers (ARBs).
The product was launched in India across select tertiary care hospitals in 2013 after the Drug Controller General of India’s approval."Elores underscores our commitment to anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infectives in India," Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla, said.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.